ALX 148

Drug Profile

ALX 148

Alternative Names: ALX 148

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator Alexo Therapeutics
  • Class Antineoplastics; Proteins
  • Mechanism of Action CD47 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 03 Feb 2017 Phase-I clinical trials in Non-Hodgkin's lymphoma (Late-stage disease) in USA (Parenteral) (NCT03013218)
  • 03 Feb 2017 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (Parenteral) (NCT03013218)
  • 15 Dec 2016 Alexo Therapeutics plans a phase I trial for Solid tumours and Lymphoma in USA (NCT03013218)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top